1 / 1

UA/NSTEMI CP < 48h, ST-Dep or +cTn, or DM, or TRS  3

UA/NSTEMI CP < 48h, ST-Dep or +cTn, or DM, or TRS  3. N = 6500. Standard Therapy. RANDOMIZE (1:1) Double-blind. Ranolazine IV to PO. Placebo Matched IV/PO. Holter at enrollment x 7d. Follow-up Q4 mo (Avg 8-12 mo). Follow-up Visits: Day 14, Month 4, Q4 Months.

leigh-mullen
Télécharger la présentation

UA/NSTEMI CP < 48h, ST-Dep or +cTn, or DM, or TRS  3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UA/NSTEMICP < 48h, ST-Dep or +cTn, or DM, or TRS  3 N = 6500 Standard Therapy RANDOMIZE (1:1) Double-blind RanolazineIV to PO Placebo Matched IV/PO Holter at enrollment x 7d Follow-up Q4 mo (Avg 8-12 mo) Follow-up Visits: Day 14, Month 4, Q4 Months Primary EPCardiovascular death, MI or recurrent ischemia Duration Event-driven Final Visit Additional endpoints: Exercise performance, extent of myocardial injury angina questionnaire, quality of life, arrhythmia

More Related